Related Experiment Video
Updated: Jan 22, 2026

Investigation of Macrophage Polarization Using Bone Marrow Derived Macrophages
Published on: June 23, 2013
Sulfasalazine-induced Pancytopenia Indicating Bone Marrow Suppression: A Rare Pediatric Case Report from Pakistan
Shayan Marsia1, Samar Mahmood1, Mohammad Raza2
1Internal Medicine, Dow University of Health Sciences (DUHS), Karachi, PAK.
Insights
Juvenile idiopathic arthritis (JIA) is a common childhood rheumatic disease. This case report details rare sulfasalazine-induced bone marrow suppression in a five-year-old child with JIA.
Area of Science:
- Pediatric Rheumatology
- Pharmacology
- Hematology
Background:
- Juvenile idiopathic arthritis (JIA) is the most prevalent chronic rheumatic condition in children.
- Current JIA management relies on pharmacotherapy, including NSAIDs, corticosteroids, and disease-modifying antirheumatic drugs (DMARDs).
- Sulfasalazine serves as a second-line DMARD, generally considered safe and effective.
Observation:
- This study presents a rare case of JIA in a five-year-old child.
- The child experienced bone marrow suppression.
- This adverse event was linked to sulfasalazine treatment.
Findings:
- Sulfasalazine, a commonly used DMARD for JIA, can induce bone marrow suppression.
- This specific adverse effect is infrequently documented in pediatric JIA patients.
- The case highlights a rare but serious complication of sulfasalazine therapy in children.
Implications:
- Clinicians should be vigilant for potential hematologic side effects of sulfasalazine in pediatric JIA patients.
- Early recognition and management of bone marrow suppression are crucial for patient outcomes.
- This case underscores the importance of monitoring and reporting rare adverse drug reactions in pediatric populations.
Abstract:
Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic condition in children. The treatment of JIA is mainly by drug therapy, which includes non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and disease-modifying antirheumatic drugs (DMARDs). Sulfasalazine is a DMARD that is used as the second-line of therapy. Although believed to have an effective and safe profile, it has side effects ranging from mild gastrointestinal discomfort to hematopoietic alterations. In this study, we present a case of JIA with sulfasalazine-induced bone marrow suppression in a five-year-old child, which is rarely reported within the pediatric age group across the literature.
Related Concept Videos
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Data Reporting and Recording
Types of Reports I: Hands-off Report
Following are the key components and categories of hand-off reports:
Purpose and Process:
Pharmacokinetics in Pediatric Patients: Drug Excretion
Types of Reports II: Incident or Occurrence Report
Purposes:
In the healthcare industry, reports play a crucial role in documenting incidents within an agency. The primary objective of these reports is to ensure patient safety, uphold the...
Pharmacokinetics in Pediatric Patients: Drug Distribution

